Products

Robenidine Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    • Product Name: Robenidine Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
    • Factroy Site: Yudu County, Ganzhou, Jiangxi, China
    • Price Inquiry: admin@ascent-chem.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    Specifications
    HS Code 777855
    Product Name Robenidine Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
    Chemical Name Robenidine hydrochloride
    Cas Number 25875-50-7
    Molecular Formula C15H13Cl2N5·HCl
    Molecular Weight 370.66 g/mol
    Appearance Yellow or yellowish crystalline powder
    Odor Nearly odorless
    Assay 98.0% - 102.0% on dried basis
    Melting Point 245°C with decomposition
    Solubility Practically insoluble in water; soluble in dimethylformamide; slightly soluble in ethanol and acetone
    Storage Conditions Keep in tightly sealed containers, protected from light, in a cool and dry place
    Shelf Life 24 months

    As an accredited Robenidine Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Robenidine Premix veterinary API packaged in sealed foil-lined bags inside drums, 25 kg net, with tamper-evident labeling.
    Container Loading (20′ FCL) 20' FCL: Robenidine Premix veterinary API loaded in sealed, moisture-proof drums/pallets, secured for safe transit.
    Shipping Robenidine Premix Veterinary Grade API is shipped in sealed, moisture-proof containers with tamper-evident packaging to ensure purity and stability. Transport is arranged under dry, temperature-controlled conditions, complying with international veterinary pharmaceutical regulations. Proper labeling and documentation accompany all shipments for safe, traceable global delivery.
    Storage Store Robenidine Premix Veterinary Grade API in its original, tightly sealed container in a cool, dry, well-ventilated area away from direct sunlight, moisture, and excessive heat. Protect from freezing and contamination. Ensure the container remains closed when not in use. Always follow manufacturer-specific storage instructions and local veterinary regulations. Keep out of reach of children and animals.
    Shelf Life Shelf life is 24 months from manufacture when stored in original, tightly sealed containers, protected from moisture and light.
    Application of Robenidine Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    Medicated Broiler Feed Incorporation at the 0.45 kg/t to 0.55 kg/t Premix Window

    In broiler compound-feed production, robenidine hydrochloride is introduced as a 66 g/kg premix rather than as neat API, because direct API addition at 30–36 mg/kg would demand per-batch quantities below the reliable resolution of most mill micro-dosing equipment. The authorised inclusion window is 0.45–0.55 kg/t complete feed for a 66 g/kg premix, corresponding to 30–36 mg/kg active in the finished ration. Compliance is anchored to Regulation (EC) No 1831/2003 Annex IV as a coccidiostat category, with feed-mill hygiene obligations under Regulation (EC) No 183/2005 Annex II and private assurance through FAMI-QS. In production-scale dry blending, a twin-shaft paddle mixer with a working volume of 85% of geometric capacity receives the robenidine premix after it has been pre-blended with 20–30 kg of ground maize or wheat middlings; the micro-dosing screw is calibrated before each campaign using a certified 5 kg check weight. Mixing continues for 4–6 minutes until 12-point sampling according to ISO 6497:2002 and ISO 6498:2012 yields a coefficient of variation below 7%. The terminal products are mash feed, 3–4 mm pellets, or crumbled equivalents. Tablet, capsule, and injectable dosage forms are not registered for broiler coccidiosis control in major regulatory jurisdictions; the established application route remains feed-grade oral administration through complete feed.

    During steam conditioning and pellet compression, the process control problem shifts from blend homogeneity to thermal and moisture stability of robenidine hydrochloride in a starch-rich matrix. The addition window remains 0.45–0.55 kg/t of the 66 g/kg premix, but the critical control point now becomes the conditioner, where saturated steam raises mash temperature to 70–85°C for a retention time of 30–90 seconds before the charge enters a pellet die with a compression ratio between 4:1 and 8:1. Compliance for this downstream segment is embedded in the HACCP plan under ISO 22000:2018, with the conditioner temperature defined as a critical control point and documented against the pellet-mill control log. The terminal product is pelleted broiler feed, subsequently crumbled where the integrated operation supplies starter feeds. Published degradation kinetic data for robenidine hydrochloride in complex feed matrices under saturated steam is limited; mills therefore run a post-pelleting HPLC assay on every tenth batch and use an internal recovery window of 90–110% of label claim. Production experience shows that cooler inlet product temperatures above 30°C create wall condensation, lipid oxidation risk, and moisture migration within the pellet bed, so counterflow coolers are set with air at 15–25°C to reduce pellet temperature to less than 5°C above ambient within 8 minutes.

    Can Rabbit Pellet Lines Maintain the 50 mg/kg to 66 mg/kg Window in High-Fibre Batches?

    In rabbit complete-feed production, the inclusion of a 66 g/kg robenidine hydrochloride premix is 0.76–1.00 kg/t, yielding 50–66 mg/kg active in the final ration. Compliance for rabbit feed mills falls under Regulation (EC) No 1831/2003 and Regulation (EC) No 183/2005, with unavoidable carryover cross-checked against Regulation (EU) No 574/2011. The production sequence begins with a coarse grind of alfalfa, soya hulls, and cereal by-products through a hammer mill fitted with a 3.0–4.0 mm screen; the robenidine premix is then micro-dosed into the main mixer before the high-fibre fraction reaches full compaction. Because rabbit rations can reach 25–30% crude fibre, the mixing time is extended to 6–8 minutes until tracer studies show a coefficient of variation below 8%. Pelleting is performed through a 6–8 mm die at a compression ratio of 4:1 to 6:1; conditioner temperature is held at 70–80°C to limit thermal stress while achieving starch gelatinisation. The terminal product is a pelleted complete feed for meat rabbits, sometimes re-crumbled for weanling rabbits. The high-fibre matrix influences robenidine distribution differently from low-fibre broiler mashes, and published data for recovery in rabbit-specific pellet configurations is limited; the mill verifies each production day with an HPLC-UV assay of the cool pellet stream before release.

    Production segmentAnimal categoryPremix strengthInclusion windowActive doseCritical process controlTerminal product
    Stationary compound-feed millBroiler chickens and replacement pullets66 g/kg0.45–0.55 kg/t30–36 mg/kgPost-mix coefficient of variation below 7%Mash, pellet, crumble
    Rabbit pellet lineMeat rabbits66 g/kg0.76–1.00 kg/t50–66 mg/kgConditioner 70–80°C; daily pellet assayPelleted complete feed
    Concentrated premix packerDownstream feed millsAssay-corrected to 66 g/kgN/AN/APost-blend coefficient of variation below 5%Concentrated premix
    Mobile mixer on-farmSmallholder broilers66 g/kg0.45–0.55 kg/t30–36 mg/kgLoad-cell verification before each batchOn-farm complete feed

    At the concentrated premix manufacturing stage, the primary downstream use is not finished feed itself but the production of a stable 66 g/kg dry premix that can be re-dosed by other mills. The formulation addition ratio is calculated by assay-corrected dilution of neat robenidine hydrochloride API against a carrier such as ground calcium carbonate or wheat bran: final activity is fixed at 66 g/kg, and the API mass is derived from the manufacturer’s certificate of analysis rather than nominal purity. Compliance is governed by FAMI-QS and ISO/IEC 17025:2017 for release analysis, with analytical method validation conducted under VICH GL2 and reversed-phase HPLC aligned to European Pharmacopoeia general method 2.2.29. Process equipment consists of a ploughshare mixer or double-ribbon blender run at 70–75% working volume; the API is first screened through a 0.5 mm sieve and pre-blended with 5–10 kg carrier before geometric dilution into the bulk batch. Mixing continues for 10–15 minutes, after which 10–12 thief samples are collected and assayed to confirm a coefficient of variation below 5%. The terminal product is a free-flowing concentrated premix, bagged in 25 kg sealed multi-wall paper sacks with polyethylene liners. Batch-to-batch variance in production-scale premix lines occurs most often when unscreened API lumps bypass the pre-blending step and create low-assay pockets that are missed by routine top sampling; this failure mode is repeatedly documented in audit records of premix packers.

    When Replacement Pullet Feeds Switch From Medicated to Non-Medicated Rations

    When replacement pullet and chicken-reared-for-laying feeds are switched from medicated to non-medicated rations, the robenidine premix must be treated as a carryover-sensitive ingredient, not as a standard micro-additive. The authorised inclusion window is 0.45–0.55 kg/t of the 66 g/kg premix, producing 30–36 mg/kg active in complete feed. The application is confined to the rearing phase; laying ration production must begin only after flushing protocols demonstrate that residue carryover is below the limits in Regulation (EU) No 574/2011. Mill-scale sequencing requires a 50–100 kg ground maize flush batch through the mixer, bucket elevator, and pellet mill after the final medicated batch, with the flush material labelled as medicated or destroyed according to national feed-safety rules. The downstream process for the medicated batch itself is dry blending for 4–6 minutes in a horizontal mixer, followed by either mash delivery or conditioning at 70–80°C for pellet and crumble production. The terminal product is a complete rearing feed for future layer and breeder flocks. This is the process segment where carryover failure is most frequently observed, because the medicated-to-clean transition occurs frequently in multi-product mills and the active dose is low enough that clean-batch retention samples can test below detection limit while a single contaminated elevator boot discharges into the next non-medicated batch.

    Directly on the farm, mobile mixer systems incorporate the 66 g/kg premix into complete feed at the same 0.45–0.55 kg/t window, but the control logic differs from stationary mills because batch volume is only 1–3 tonnes and load-cell drift becomes the dominant error source. Operators are subject to registration and inspection under Regulation (EC) No 183/2005 Annex II and national feed-hygiene provisions; the premix itself remains a complying feed additive under Regulation (EC) No 1831/2003. The addition is made after the cereal base has been loaded into the vertical auger mixer, and circulation continues for 10–12 minutes after the premix is metered through a low-rate screw calibrated with a certified 1 kg check weight. Batch control requires the load cell to be verified before each batch because the required premix quantity for a 2-tonne batch is only 0.9–1.1 kg; a drift of 0.5% full scale can shift the final active concentration outside the legal window. The terminal product is complete feed for on-farm broiler consumption, either as meal or processed through mobile pelleting units. Tablet, capsule, and injectable intermediate forms are not encountered in this downstream route; the practical presentation remains the dry concentrated premix with particle-size control below 1 mm to prevent segregation during auger mixing.

    Free Quote

    Competitive Robenidine Premix Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615365186327

    Email: admin@ascent-chem.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Robenidine Premix Veterinary Grade API is the hydrochloride salt of the synthetic guanidine-derivative coccidiostat robenidine, supplied as an active-substance feedstock for tablets, injections, capsules, powders, granules, premixes, and solutions. The product is designated RBD-HCl-VET-PMX and is not a diluted feed-additive premix; it contains no carrier, anti-caking agent, flow aid, or release-modifying excipient. The active molecule is identified by CAS 25875-51-8, with molecular formula C15H13Cl2N5·HCl and relative molecular mass 370.66 g/mol. The material appears as a white to pale yellow crystalline powder. It is intended for further pharmaceutical manufacture under active-substance good manufacturing practice and appropriate containment. Batch release is performed against a veterinary active-substance specification that includes assay, related substances, residual solvents, loss on drying, particle-size distribution, and microbial limits. Because the same active substance can be requested for dry oral solids, feed premixes, and sterile injectables, the formulator must distinguish between compendial acceptability and fitness for the individual route of administration.

    Release specification parameters for multi-dosage-form feedstock

    The following release limits are applied to the premix-grade hydrochloride. Values are typical veterinary active-substance controls and should be confirmed against the applicable regional pharmacopoeial monograph or registered active-substance master file.

    Parameter Release Limit Method / Standard
    Assay on dried basis 97.0–102.0% HPLC with UV detection at 254 nm; external standard
    Loss on drying 0.5% Drying at 105 °C to constant weight
    Related substances, any unspecified impurity 0.5% HPLC area normalisation
    Related substances, total impurities 2.0% HPLC area normalisation
    Residual methanol 3000 ppm Headspace GC; ICH Q3C / VICH GL18
    Residual N,N-dimethylformamide 880 ppm Headspace GC; ICH Q3C / VICH GL18
    Elemental impurities Complies with option-based limits ICP-MS; ICH Q3D
    Particle size, D90 75 µm Laser diffraction; ISO 13320:2020
    Bulk density 0.35–0.65 g/cm³ USP 616
    Microbial limits TAMC ≤ 103 CFU/g; TYMC ≤ 102 CFU/g; Escherichia coli absent Ph. Eur. 5.1.4

    Particle-size distribution exerts a first-order effect on premix homogeneity because robenidine hydrochloride is commonly incorporated at low mass fractions in finished medicated feed. When the final feed inclusion is below 100 mg/kg, segregation of coarse active particles becomes analytically detectable as a non-uniform distribution of assay values across sampling points. Production-scale equipment such as horizontal ribbon blenders and paddle mixers requires staged geometric dilution at 1:10 or tighter ratios, followed by triplicate sampling from top, middle, and discharge zones. The observed coefficient of variation should remain below 5% for a validated batch. Dry powder and capsule filling may require a finer milled grade with D9020 µm, while direct blending into vitamin-mineral premixes may tolerate the standard ≤ 75 µm grade if bulk density and electrostatic charging are controlled. Ambient relative humidity above 60% may increase cohesion and screw-feeder adhesion; pre-drying should only be introduced after loss-on-drying data demonstrate a moisture excursion, because uncontrolled thermal drying can alter electrostatic charge and downstream flow.

    When tablets, capsules, or granules are the target dosage forms

    For low-dose solid oral dosage forms, direct compression of the ≤ 75 µm grade is frequently unsuited to content uniformity requirements unless the formulation includes a pre-blended trituration with silicified microcrystalline cellulose or lactose monohydrate. High-shear wet granulation is the more conservative route when the robenidine mass fraction is below 5% of the core weight. An aqueous or hydroalcoholic binder solution of povidone K30 at 2–5% w/w is applied in a high-shear granulator, with impeller tip speed selected to avoid over-wetting and agglomerate formation. Fluid-bed drying is terminated at a granule moisture endpoint of 1.0–2.0%; drying below this window can increase friability, while drying above it can promote punch sticking during compression. Magnesium stearate is added at 0.5–1.0% w/w and blended for 3–5 minutes; extended lubrication beyond this interval reduces tablet hardness and increases disintegration time. Tablet hardness is maintained in the range of 40–80 N for immediate-release cores, and disintegration is assessed according to Ph. Eur. 2.9.1 or USP 701. Dissolution testing for solid oral dosage forms uses compendial media such as 0.1 M hydrochloric acid or phosphate buffer pH 6.8; the selection of medium must be justified by experimental solubility data because the molecule is a weak base with pH-dependent aqueous solubility.

    Why is the hydrochloride salt preferred over the free base for premix and solution formulations?

    The hydrochloride salt is preferred because it provides a defined salt stoichiometry, improved handling relative to the free base, and controlled protonation for acidic aqueous processing. The free base is poorly water-soluble at neutral pH and is not a direct substitute for the hydrochloride in premix or solution applications. In aqueous media, the hydrochloride salt exhibits pH-dependent solubility; dissolution is more favourable below pH 3, while neutral pH solubility remains limited. For injectable solutions, the formulation must therefore be designed around a co-solvent system or pH adjustment, not by simple dissolution in water for injection. Liquid formulations intended for parenteral use require sterile filtration through a 0.22 µm membrane validated for the specific formulation according to ASTM F838-20. Where terminal sterilisation is not feasible because of vial headspace or heat-transfer constraints, aseptic processing is required. Published data for robenidine hydrochloride in ready-to-use sterile injectable formulations is limited; therefore, the formulator must generate solubility, pH, and stability data for the intended vehicle rather than assume direct transfer from feed premix compounding.

    For formulators, the practical boundary is excipient compatibility

    The molecule contains azomethine linkages and should be protected from prolonged aqueous contact under strongly acidic or strongly alkaline conditions, which can increase the rate of hydrolytic formation of 4-chlorobenzaldehyde-related impurities. Granulating fluids below pH 2 or above pH 9 should be avoided unless forced-degradation studies demonstrate acceptable impurity control. Oxidising agents, strong bases, and metal-salt catalysts should not be blended with the active substance without compatibility screening. For premix and granule manufacture, the API is generally compatible with calcium carbonate, cornstarch, lactose, and mineral carriers, but amine-rich conditioning agents should be avoided because of potential adduct formation or pH drift during storage. Storage at controlled room temperature with relative humidity not exceeding 60% is recommended; if the container is opened in high-humidity environments, the closure should be resealed with desiccant and the material re-tested for loss on drying before use.

    Assessing comparability between veterinary-grade API, technical-grade material, and diluted premixes

    Veterinary premix-grade robenidine hydrochloride differs from technical-grade material and from diluted feed premixes in a way that directly determines dosage-form utility. Technical-grade robenidine may be manufactured without the same related-substance, residual-solvent, elemental-impurity, and microbial controls required for active-substance GMP supply. It is not suitable for tablets, capsules, injectables, or oral solutions. A diluted feed premix contains robenidine on a carrier such as calcium carbonate or rice hulls and is intended solely for final feed mixing; it cannot be used as a feedstock for sterile or solid oral dosage forms because the carrier particles, content uniformity, and release controls are not appropriate for pharmaceutical manufacture.

    Attribute RBD-HCl-VET-PMX Technical-grade robenidine Diluted feed premix
    Related-substance release testing Yes; individual unspecified impurity ≤ 0.5% Often not batch-to-batch controlled Not applicable to carrier-containing mixture
    Residual solvents Controlled per ICH Q3C / VICH GL18 May be uncontrolled Not typically tested
    Elemental impurities Controlled per ICH Q3D May reflect technical-grade metal residues Carrier-dependent
    Tablet or capsule feedstock Suitable with formulation development Not suitable Not suitable
    Injectable solution feedstock Suitable only with solubility enhancement and sterilisation validation Not suitable Not suitable
    Premix homogeneity control Particle size controlled by laser diffraction Variable, not release-controlled Carrier particle size dominates

    In target species, robenidine is used as an anticoccidial in poultry and rabbit production, with administration generally through medicated feed. The active substance is a synthetic guanidine derivative, not a polyether ionophore, and is not interchangeable on an equal-mass basis with monensin, narasin, salinomycin, or lasalocid. Route-of-administration suitability is governed by regional licensing, target-species tolerability, and withdrawal period data; the API itself does not confer those regulatory properties. For oral solution or powder formulations, the dose must be adjusted by body weight and mixed or dosed in a manner that minimises sedimentation and cross-contamination in automated water-medication systems. For solid oral dosage forms, content uniformity and dissolution rate are controlled by the formulation and granulation process, not by the API lot alone. The premix-grade active substance is therefore a starting point for multiple dosage forms, but each finished product requires separate pharmaceutical development, stability evaluation, and regulatory demonstration of safety and efficacy.

    Top